Mandate

Vinge advises Yubico in the merger with ACQ Bure  

ACQ Bure AB, a Swedish acquisition company (Special Purpose Acquisition Company) listed on Nasdaq Stockholm and Yubico AB have signed a merger agreement and adopted a joint merger plan to combine ACQ and Yubico.

Yubico is a leading provider of multi-factor cybersecurity solutions. Yubico’s hardware-based security key, YubiKey, is a leading solution for protection against phishing attacks, and works across hundreds of consumer and enterprise applications and services. Yubico’s technology enables secure authentication, encryption, and code signing and is used by many of the world’s largest organizations and millions of users in more than 160 countries

The transaction values Yubico’s shares at 800 MUSD and is expected to be completed during the third quarter 2023, subject to, among other things, approval by the general meeting in ACQ and Yubico, respectively.

Vinge’s team consisted of Jonas Johansson, Maria Dahlin Kolvik and Gustav Wahlberg (M&A) as well as Linnea Sellström (Public M&A).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026